Antonio Anzueto, MD
Pulmonary Disease · San Antonio, TXNPI 1053428128
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,142,631 of the $1,824,809 with a category attached, or 62.6%. 33 manufacturers reported payments, led by GSK at 38.4% of the total. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,551 payments — averaging $1176.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$700K
- AstraZeneca$243K
- Mylan Specialty L.p.$181K
- Sanofi$139K
- Astrazeneca UK Limited$85K
- Boehringer Ingelheim$84K
- plus $392K from 27 others
Across 24 payments — averaging $1193.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$19K
- Sanofi$5K
- Teva Pharmaceuticals USA, Inc.$3K
- Chiesi USA, Inc.$2K
- GSK$650
What the payments were for
- Consulting fees$407,34822%
- Speaking & faculty fees$1,142,63163%
- Travel & lodging$247,74914%
- Food & beverage$24,4211%
- Education$1430%
- Gifts$170%
- Charitable contribution$2,5000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 578 | $700,466 |
| AstraZeneca | 229 | $242,811 |
| Mylan Specialty L.p. | 232 | $180,892 |
| Sanofi | 49 | $139,104 |
| Astrazeneca UK Limited | 78 | $85,266 |
| Boehringer Ingelheim | 60 | $84,467 |
| Regeneron Healthcare Solutions, Inc. | 40 | $55,871 |
| Sunovion Pharmaceuticals Inc. | 49 | $36,062 |
| Boehringer Ingelheim International GmbH | 24 | $31,470 |
| Viatris Specialty LLC | 32 | $30,578 |
| Teva Pharmaceuticals USA, Inc. | 10 | $27,834 |
| Grifols USA, LLC | 38 | $26,767 |
| Regeneron | 17 | $20,186 |
| Boehringer Ingelheim Hong Kong Ltd. | 11 | $18,815 |
| Mylan Inc. | 9 | $18,573 |
| Verona Pharma, Inc. | 13 | $16,950 |
| Boehringer Ingelheim Mexico SA De CV | 15 | $14,950 |
| Abbott | 5 | $14,833 |
| Pfizer | 13 | $13,200 |
| Merck | 16 | $12,203 |
| Boehringer Ingelheim Singapore Pte. Ltd. | 5 | $11,874 |
| Novartis | 2 | $9,585 |
| Boehringer Ingelheim Malaysia Sdn. Bhd. | 3 | $7,187 |
| Astrazeneca AB | 4 | $7,128 |
| Viiv Healthcare Company | 3 | $6,070 |
| Boehringer Ingelheim S.A. | 3 | $4,705 |
| Genentech, Inc. | 1 | $2,640 |
| Chiesi USA, Inc. | 6 | $2,276 |
| Janssen Global Services, LLC | 1 | $1,150 |
| Boehringer Ingelheim (china) Investment Co., Ltd. | 1 | $488 |
| Partner Therapeutics, Inc. | 1 | $350 |
| Gilead | 2 | $45 |
| Insmed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$240,089
- TRELEGY ELLIPTA$222,211
- Yupelri$202,388
- BREZTRI$178,512
- AREXVY$166,571
- STIOLTO RESPIMAT$100,929
- LONHALA MAGNAIR$34,573
- NUCALA$19,721
- Prolastin-C$18,828
- Ohtuvayre$16,920
- SPIRIVA$16,100
- STIOLTO$15,767
- AirDuo Digihaler$15,284
- SPIRIVA RESPIMAT$13,714
- BREZTRI AEROSPHERE$11,058
- ProAir Digihaler$9,849
- ArmonAir Digihaler$8,849
- AIRSUPRA$8,664
- Prolastin-C Liquid$7,605
- AirDuo RespiClick$7,190
How this compares
$1,824,809 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $62,794 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $45,687 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $39,942 |
| Spiriva RespimatTiotropium Bromide | 35 | $32,329 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $21,746 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $7,452 |
| Spiriva HandihalerTiotropium Bromide | 12 | $7,344 |
| DuleraMometasone/Formoterol | 11 | $3,401 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $1,996 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,190 |
| Olopatadine Hcl | 11 | $840 |
| Azithromycin | 26 | $250 |
| Montelukast Sodium | 27 | $229 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $115 |
| Prednisone | 24 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $700,466 | $110,188110 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $84,467 | $54,07554 claims |
| AstraZenecaBreztri Aerosphere | $242,811 | $45,68750 claims |
| MerckDulera | $12,203 | $3,40111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in San Antonio
- Diego Maselli CaceresSan Antonio$1.5M
- David MarksSan Antonio$453K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Ali AbediSan Antonio$269K
- Napoleon Puente CuellarSan Antonio$208K
- Soma JyothulaSan Antonio$129K
- Anoop NambiarSan Antonio$119K
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.